Skip to main content
Signal8

BriaCell and BriaPro Present Positive Preclinical Immunotherapy Data Across Four Posters at SITC 2026

$BCTXPress releaseNov 6, 2026, 9:00 AM ET

BriaCell and its majority-owned subsidiary BriaPro presented four posters of positive preclinical immunotherapy data at the SITC 41st Annual Meeting in Phoenix, Nov. 4-8, 2026. Key findings include broad immune activation and sustained cancer-cell killing from the Bria-OTS+ platform, BP-80 tolerability in a four-week GLP nonhuman primate study with a NOEL of 50 mg/kg/dose, and engineered CD80 constructs showing 49-fold and 130-fold-plus improved PD-L1 binding affinity.

Key figures

Bp80 noel
50 mg/kg/dose
Cd80 fc pd-l1 affinity improvement
more than 130-fold stronger PD-L1 binding
Tilsrx001 pd-l1 affinity improvement
49-fold higher PD-L1 binding affinity

AI analysis

The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.

AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.